MedTrace Logo

Study of the Nasal Intracellular Reservoir of Staphylococcus Aureus in Patients With S. Aureus Bacteremia

NCT06594250 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 405

Last updated 2024-09-19

No results posted yet for this study

Summary

Staphylococcus aureus bacteremia is a serious infection associated with a high mortality rate (with or without associated infective endocarditis (IE)), long hospital stays and multiple complications, due to the terrain in which it occurs and its secondary localization. They may be community-acquired or healthcare-associated infections. Being a carrier of S. aureus is a known risk factor for S. aureus bacteremia. Although several mucosal sites of carriage have been described, screening for carriage is most often carried out at the nasal level, both for reasons of simplicity and because it is the predominant site of carriage of this bacterium. However, S. aureus carriage is a frequent occurrence, affecting around 1/3 of the general population.

Conditions

  • Bacteria Infection Mechanism

Interventions

DIAGNOSTIC_TEST

Nasal swab

Nasal swab to detect nasal carriage of S. aureus

BIOLOGICAL

Venous sampling

Peripheral venous sampling to collect peripheral blood mononuclear cells.

BIOLOGICAL

Antibiotic treatment

Antibiotic treatment for bacteremia (+/- 1 month), in all patients with S. aureus

DEVICE

Nasal swab

A new nasal swab will be taken using the same technique, to see whether or not the carriage persists

BIOLOGICAL

Intracellular reservoir test

In the event of positive carriage, a new intracellular reservoir test will be performed. A search for relapse (new S. aureus infection) or recurrence (S. aureus bacteremia if the 1st bacteremia was due to another pathogen) will be carried out.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Elisabeth BOTELHO-NEVERS, MD-PhD · CHU SAINT-ETIENNE

  • Léo SAUVAT, MD · CHU SAINT-ETIENNE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-02
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06594250 on ClinicalTrials.gov